Publications by authors named "Stephen Shuttleworth"

Claim this Profile
F
Functional characterization of a novel somatic oncogenic mutation of .
Andrew D Whale, Lucy Colman, Letitia Lensun, Helen L Rogers, Stephen J Shuttleworth

Signal Transduct Target Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
David Gyori, Ee Lyn Lim, Francis M Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J Shuttleworth

JCI Insight· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.
Jonathan D Ellis, Desley A H Neil, Nick G Inston, Eric Jenkinson, Mark T Drayson, Stephen J Shuttleworth

Transplantation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Daniel P Sutherlin, Stewart Baker, Angelina Bisconte, Paul M Blaney, Anthony Brown, Stephen Shuttleworth

Bioorg Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Brian S Safina, Stewart Baker, Matt Baumgardner, Paul M Blaney, Bryan K Chan, Stephen Shuttleworth

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
Timothy P Heffron, Binqing Wei, Alan Olivero, Steven T Staben, Vickie Tsui, Stephen Shuttleworth

J Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.
Stephen Shuttleworth, Paul Townsend, Franck Silva, Alexander Cecil, Thomas Hill

Prog Med Chem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.
Stephen Shuttleworth, Franck Silva, Cyrille Tomassi, Alexander Cecil, Thomas Hill

Prog Med Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.
Jonathan M Large, Jane E Torr, Florence I Raynaud, Paul A Clarke, Angela Hayes, Stephen J Shuttleworth

Bioorg Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.
Stephen J Shuttleworth, Sarah G Bailey, Paul A Townsend

Curr Drug Targets· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a novel Neuromedin B receptor antagonist.
Jiasheng Fu, Stephen J Shuttleworth, Richard V Connors, Anne Chai, Peter Coward

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Florence I Raynaud, Suzanne A Eccles, Sonal Patel, Sonia Alix, Gary Box, Stephen Shuttleworth

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.
Marketa J Zvelebil, Michael D Waterfield, Stephen J Shuttleworth

Arch Biochem Biophys· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, Sonia Alix, Stewart J Baker, Stephen J Shuttleworth

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the specificity of the PI3K family inhibitor LY294002.
Severine I Gharbi, Marketa J Zvelebil, Stephen J Shuttleworth, Tim Hancox, Nahid Saghir

Biochem J· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization.
Stephen J Shuttleworth, Richard V Connors, Jiasheng Fu, Jinqian Liu, Mike E Lizarzaburu

Curr Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimization of novel partial agonists of neuromedin B receptor using parallel synthesis.
Stephen J Shuttleworth, Mike E Lizarzaburu, Anne Chai, Peter Coward

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis